Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Any side effects from generic lyrica?

See the DrugPatentWatch profile for lyrica

Common Side Effects of Generic Lyrica (Pregabalin)

Generic Lyrica contains pregabalin, used for nerve pain, fibromyalgia, and seizures. Side effects match the brand-name version and include dizziness (up to 45% of users), drowsiness (up to 36%), dry mouth (15%), swelling in hands/feet (14%), blurred vision (12%), weight gain (10%), and trouble concentrating (9%)[1][2].

Serious Side Effects and Warnings

Rare but severe risks involve allergic reactions (rash, swelling, breathing issues), suicidal thoughts (0.1-1% risk, higher in younger patients), muscle pain with fever, vision changes, or easy bruising. Abrupt stopping can cause insomnia, nausea, headache, or seizures. FDA warns of misuse potential leading to euphoria or dependence[1][3].

Side Effects by Condition Treated

For neuropathic pain or fibromyalgia: Higher rates of dizziness and somnolence. Epilepsy patients report more weight gain and coordination issues. Generalized anxiety: Fatigue and headache more common[2][4].

Who Gets Hit Hardest by Side Effects

Elderly users face amplified dizziness and falls risk. Those with kidney issues need dose cuts, as pregabalin clearance drops 50% in severe cases. Pregnant users: Possible birth defects; avoid unless essential[1][3].

How Long Do Side Effects Last

Most (dizziness, sleepiness) peak in first 1-2 weeks and fade with continued use. Weight gain builds over months. Withdrawal symptoms emerge 24-48 hours after stopping[2].

Managing or Avoiding Side Effects

Start low (75mg/day) and titrate slowly. Take with food to ease stomach upset. Avoid alcohol, driving until adjusted. Report persistent issues to doctor; alternatives like gabapentin may suit better[1][4].

Compared to Brand-Name Lyrica

No difference—generics are bioequivalent, with identical active ingredient and side effect profile per FDA approval[1].

[1]: FDA Label for Pregabalin (Generic Lyrica), https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021446s056lbl.pdf
[2]: Pfizer Lyrica Prescribing Information, https://labeling.pfizer.com/showlabeling.aspx?id=561
[3]: Drugs.com Side Effects Database, https://www.drugs.com/sfx/lyrica-side-effects.html
[4]: Mayo Clinic Pregabalin Overview, https://www.mayoclinic.org/drugs-supplements/pregabalin-oral-route/side-effects/drg-20067411



Other Questions About Lyrica :

Does alcohol reduce lyrica s effectiveness for seizures? Should lyrica dosage increase with heavy workouts? Why seek alternatives to long term lyrica use? Have you updated doctor on lyrica s impact on you? Any adverse effects of combining lyrica with bp meds? Does lyrica dosage change with intense workout? How often should lyrica be taken in smaller doses?

AI-Drug Label Prescribing Information Alignment Report

69
69%
Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

The evaluation accurately identifies many limitations in the supplied label, including the approved indication scope, renal dose adjustment, and several adverse-reaction claims. However, its corrections assert pregnancy and alcohol information that is not present in the supplied label, and some initial judgments overstate what the label's aggregate adverse-reaction rates establish.


Category Scores

Indication
92
Excellent
Dosage
85
Good
Warnings
75
Good
DrugInteractions
55
Partial
SpecificPopulations
60
Partial
AdverseReactions
72
Partial
Dosage
85
Good

Accurate Statements

The label approves pregabalin for fibromyalgia and for adjunctive treatment of partial-onset seizures in patients 1 month of age and older, rather than seizures generally.
Section 1 lists these specific indications.
The label requires dose adjustment for adults with reduced renal function.
Sections 2.1 and 2.7 direct renal dose adjustment.
The label does not provide the claimed 24–48-hour withdrawal onset or a universal starting dose of 75 mg/day with slow titration in the supplied sections.
Sections 2.1, 2.7, and 5.6 provide renal dosing and withdrawal information but do not state those claims.
The label reports increased suicidal-thought or behavior risk with antiepileptic drugs, including Lyrica, and says risk did not vary substantially by age.
Section 5.3.

Unsupported Statements

Section 8.1 discusses animal findings and human observational data suggesting increased risk of major congenital malformations.
The supplied label contains only the Section 8.1 heading and no pregnancy text to support this assertion.
The label weighs potential benefit against fetal risk and supports avoiding pregabalin unless essential.
No pregnancy recommendations or risk discussion are included in the supplied label content.
The prescribing information advises patients to avoid alcohol while taking Lyrica because of additive effects on cognitive and gross motor functioning.
The supplied Section 7 and Section 17 excerpts contain no alcohol warning or such counseling instruction.
The label discusses physical dependence in Section 9.3.
Section 9.3 is not supplied. The supplied label discusses misuse or abuse in Section 9.1 and euphoria in Section 9.2, but does not establish the asserted Section 9.3 content.
The initially marked contradictions for dizziness and somnolence fading with continued use are disproven by the persistence percentages.
The label reports persistence until the last dose in a subset of affected patients; that does not establish that symptoms cannot fade in other patients. The response later correctly recognizes this limitation.

Contradictions


Important Omissions

When discussing symptoms after abrupt or rapid discontinuation, the evaluation does not highlight the label instruction to taper gradually over a minimum of 1 week.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Most claim assessments are cautious and label-grounded, but the unsupported pregnancy and alcohol assertions could be mistaken for instructions or warnings established by the supplied prescribing information. The response also initially treats limited persistence data as proof that symptoms do not fade.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Moderate

Recommendation

Partially Aligned

Primary Issue
The correction section relies on pregnancy and alcohol-label content not included in the supplied prescribing information, while some initial adverse-reaction judgments overinterpret aggregate trial rates.

Suggested Improvement
Restrict corrections to the supplied label text, identify pregnancy and alcohol claims as not assessable from the provided excerpts, and distinguish evidence of persistence in some patients from evidence that symptoms never fade.

Drug Brand Mention Assessment

Branding Score
44
Visibility
79
Mentioned
Ranking
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • Generic Lyrica contains pregabalin.
  • Generic and brand-name Lyrica have matching side-effect profiles.
  • Common side effects include dizziness, drowsiness, dry mouth, swelling, blurred vision, and weight gain.
Differentiators

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
gabapentin 25%
65 # Yes